ANGLE plc: Issue of Share Options
(firmenpresse) - GUILDFORD, SURREY -- (Marketwired) -- 11/28/16 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)
AIM: AGL; OTCQX: ANPCY
("ANGLE" or the "Company")
ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that under the shareholder approved Remuneration Policy the Remuneration Committee has approved the issue of 1,500,000 share options to the Company''s executive directors. The Remuneration Committee has also approved the issue of 1,805,000 share options to certain staff.
Following the issue of these share options, the Company will have outstanding options over a total of 10,365,806 ordinary shares of £ 0.10, representing approximately 11.6% of its issued and to be issued share capital. This leaves approximately 3.9 million options unallocated within the approved limit of up to 16% of the issued and to be issued share capital from time to time.
The exercise price for the new share options is 64.50 pence per share, representing the Company''s closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions.
The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued.
Following the issue of the new share options, the total number of share options held by the executive directors of the Company will be:
The non-executive directors do not hold share options.
For Frequently Used Terms, please see the Company''s website on
ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.
ANGLE''s cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here
The analysis of the cells that can be harvested from patient blood with ANGLE''s Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug''s effectiveness.
As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.
ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit:
Contacts:
RNS
Customer Services
0044-207797-4400
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.11.2016 - 03:18 Uhr
Sprache: Deutsch
News-ID 1472246
Anzahl Zeichen: 2574
contact information:
Contact person:
Town:
GUILDFORD, SURREY
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 302 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ANGLE plc: Issue of Share Options
"
steht unter der journalistisch-redaktionellen Verantwortung von
ANGLE plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
